Last reviewed · How we verify

Hyalgan (sodium hyaluronate)

Sanofi · FDA-approved active Small molecule

Sodium hyaluronate is a viscoelastic substance that lubricates and cushions joints by mimicking the properties of natural synovial fluid.

Sodium hyaluronate is a viscoelastic substance that lubricates and cushions joints by mimicking the properties of natural synovial fluid. Used for Osteoarthritis of the knee.

At a glance

Generic nameHyalgan (sodium hyaluronate)
SponsorSanofi
Drug classViscosupplement
TargetSynovial fluid replacement (non-receptor mediated)
ModalitySmall molecule
Therapeutic areaRheumatology / Orthopedics
PhaseFDA-approved

Mechanism of action

Hyaluronic acid is a naturally occurring polysaccharide found in synovial fluid that provides lubrication and shock absorption in joints. When injected intra-articularly, sodium hyaluronate restores the viscoelastic properties of degraded synovial fluid, reducing friction between cartilage surfaces and providing mechanical protection. This viscosupplementation approach helps alleviate pain and improve joint function in osteoarthritis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: